| Description: |
Marius Rohde,1,* Vijay Kumar Singh,1,* Andrea Wolfermann,1 Birgit Burkhardt,2 Claudia Blattmann,3 Daniel Steinbach,4 Dominik T Schneider,5 Martin Ebinger,6 Britta Maecker-Kolhoff,7 Matthias Braun,1 Lars Kurch,8,9 Christine Mauz-Körholz,1,10 Dieter Körholz1 1Department of Pediatric Oncology, Hematology and Immunodeficiencies, Justus-Liebig-University, Giessen, Germany; 2Department of Pediatric Hematology and Oncology, University Children’s Hospital Muenster, Muenster, Germany; 3Pediatric Oncology, Hematology, Immunology, Klinikum Stuttgart-Olgahospital Stuttgart Cancer Center, Stuttgart, Germany; 4Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany; 5Clinic of Pediatrics, Dortmund Municipal Hospital, University Witten/Herdecke, Dortmund, Germany; 6Department of Paediatric Hematology, Oncology, Gastroenterology, Nephrology and Rheumatology, University Children’s Hospital Tübingen, Tübingen, Germany; 7Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; 8Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany; 9Department of Anesthesiology and Operative Intensive Care, University Hospital Halle (Saale), Halle (Saale), Germany; 10Medical Faculty, Martin-Luther University of Halle-Wittenberg, Halle, Germany*These authors contributed equally to this workCorrespondence: Marius Rohde, Department of Pediatric Oncology, Hematology and Immunodeficiencies, Justus-Liebig-University, Feulgenstraße 10-12, Giessen, 35392, Germany, Tel +49 641 985 43421, Fax +49 641 985 43429, Email Marius.Rohde@paediat.med.uni-giessen.deAbstract: Pediatric Hodgkin lymphoma (HL) is highly curable, and reducing the treatment intensity in patients who respond well to induction therapy is a key strategy for minimizing long-term adverse effects. Biomarkers that identify good responders at diagnosis would enable further de-escalation of the treatment. Circulating microRNAs (miRNAs) have shown promise as noninvasive indicators of ... |